Upgrade to SI Premium - Free Trial

Sarepta (SRPT) Bullish View Reiterated at Credit Suisse at EXONDYS51 Gains Momentum

April 28, 2017 6:45 AM
Credit Suisse analyst Alethia Young reiterated an Outperform rating and $64 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles